7 results
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
and Management ... 40, F:M 9:1 • Clinical ... Manifestations: Malar rash ... - pANCA anti-MPO ... #Summary #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
to 1:1 F:M • Clinical ... NPSLE rare, Malar rash ... - pANCA anti-MPO ... - pANCA anti-MPO ... #table #rheumatology
SLE (Systemic Lupus Erythematosus)

Suspect:
Clinical evidence of (fatigue, rash, photosensitivity, inflammatory arthritis, weight loss, and fever) and
SLE (Systemic Lupus ... ) Suspect: Clinical ... Skin Disease Classification ... permanent alopecia Differential ... Malignancy (e.g. hematologic
Vasculitis and Vasculitides - Differential Diagnosis Framework

When to Consider Vasculitis:
 • Purpura, ischemic skin lesions
 •
inflammation Others: • Lupus ... mucositis - Rash ... such as systemic lupus ... vasculitis, and SLE ... #classification
Monkeypox

What?
Monkeypox virus belongs to the family Poxviridae, subfamily Chordopoxvirinae, and genus orthopoxvirus
Viral zoonotic disease that is
Characteristic Rash ... • Fomites • Live ... three weeks Clinical ... rectal pain, rectal bleeding ... #Diagnosis #Management
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
Petechial or purpuric rash ... erythematosus [SLE ... thrombocytopenia • Liver ... Syndrome #Diagnosis #Management ... #Hematology #Rheumatology
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
to 1:1 F:M • Clinical ... NPSLE rare, Malar rash ... - pANCA anti-MPO ... #DIL #rheumatology ... diagnosis #treatment #management